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PlasmaWe have described that MMP-9 C−1562T and (CA)n polymorphisms contribute to multiple sclerosis (MS).
Here, we evaluate whether plasma MMP-9 levels are related to disease severity, drug therapy resistance
and polymorphisms. For sub-study 1, 36 patients with MS and 35 controls were recruited. For sub-study 2,
88 individuals (53 patients and 35 controls) were included in a cross-sectional analysis. MS patients pre-
sented higher MMP-9 activity (1.4±0.18 versus 0.93±0.18 A.U. for control, Pb0.05). Drug-therapy resistant
individuals exhibited increased MMP-9 activity (1.96±0.25 versus 1.21±0.09 A.U. for non-resistant pa-
tients). EDSS score was also related to MMP-9 levels. The CT+TT and HH genotypes had higher MMP-9 levels
as compared to patients carrying the CC and LL. Drug therapy resistance, disease severity, MMP-9 plasma ac-
tivity and polymorphisms are associated with MS.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Multiple sclerosis (MS) is considered to be a chronic neurological
cell mediated autoimmune disease. The relapsing–remitting phase of
the disease is associated with bursts of white matter inﬂammation in
the brain and spinal cord, which causes focal demyelination followed
or not by incomplete remyelination and gliosis (scarring). Axonal
and neuronal damage predominates during the chronic phase. Accu-
mulation of myelin loss and axonal damage over time often culmi-
nates in disabling central nervous system (CNS) disease. The lesions
are mainly triggered by autoreactive inﬂammatory cells migrating
through the damaged blood–brain barrier (BBB) into the CNS
(Hauser and Oksenberg, 2006; Hauser, 2008).
Matrix metalloproteinases (MMPs), particularly MMP-9, seem to
be essential for inﬂammatory cell migration to the CNS in MS
(Gijbels et al., 1992, 1993; Lee et al., 1999). MMP-9 levels have been
found to be augmented in the serum and cerebrospinal ﬂuid of MS
patients (Gijbels et al., 1992; Liuzzi et al., 2002; Avolio et al., 2003;
Boz et al., 2006; Fainardi et al., 2006). Moreover, circulating MMP-9
levels have been considered to be a therapeutic response biomarkerces, Medical School of Ribeirão
14049-900, Ribeirão Preto, SP,
.
vier OA license.to IFN-beta (Comabella et al., 2009; Alexander et al., 2010), a drug
that is commonly employed in the treatment of MS. In addition, the
transcriptional activity of the MMP-9 gene may be inﬂuenced by
two polymorphisms in the promoter region, namely the microsatel-
lite (CA)n 13–25 (rs3222264) and the single nucleotide C−1562T
(rs3918242) polymorphisms (Shimajiri et al., 1999; Zhang et al.,
1999). Our group has demonstrated that association of variants of
these two polymorphisms is related to MS (Fernandes et al., 2009).
Therefore, the aim of the current study was to compare the plasma
MMP-9 levels of MS patients and healthy controls (sub-study 1),
and to verify whether the MMP-9 levels are related to the clinical sta-
tus or resistance to drug therapy. In addition, we have evaluated
whether the (CA)n 13–25 and C−1562T polymorphisms modulate
plasma MMP-9 activities in MS patients and control subjects (sub-
study 2).
2. Materials and methods
2.1. Subjects
This study was approved by the Ethics Committee of the Medical
School of Ribeirão Preto, University of Sao Paulo, Brazil. All the partic-
ipants signed a written informed consent. All the patients were trea-
ted with one of the following immunomodulating agents: interferon
beta-1a, interferon beta-1b, or acetate glatiramer. Sub-study 1 was
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rolled for it. More speciﬁcally, the study group consisted of 36 pa-
tients (all Caucasian, 83% female, aged 38±12 years) fulﬁlling the
revised McDonald's criteria for MS (Polman et al., 2005). All the pa-
tients were recruited from the Division of Neuroimmunology of the
University Hospital of the Medical School of Ribeirão Preto and
were examined by the same neurologists (DGB and AAB) at the MS
center of the Division. The control group was matched to the MS
group for age (39±13 years), ethnicity (all Caucasian), and gender
(86% female). It consisted of 35 healthy subjects recruited from the
general community, with no family history of MS or any other auto-
immune diseases. Fifty-three patients (Caucasian, 84% female, and
38.5±12 years) were recruited for the sub-study 2. Besides the con-
ventional neurological examination, the disability degree was evalu-
ated by using the Clinical Expanded Disability Status Scale (EDSS)
(Kurtzke, 1983). Thirty six percent of the patients had EDSS between
0.0 and 2.0 (n=19); 29% had EDSS in the range of 2.5–4.0 (n=16);
27% had EDSS lying between 4.5 and 6.0 (n=14), and 8% had EDSS
ranging from 6.5 to 8.0 (n=4). Response to treatment was assessed
by a single neurologist in a blinded fashion on the basis of review of
medical records and relapse diaries. Patients who had remained
relapse-free for ≥24 months on their current drug therapy regimen
were classiﬁed as responders (n=37), irrespective of the dose.
Those who had continued to experience relapses over the previous
24 follow-up months despite prior exposure to appropriate drug
therapy regimens were considered to be non-responders (n=16).
The same control group (n=35) was included in sub-study 2, to ver-
ify the effect of MMP-9 polymorphisms on MMP-9 activity.Healthy MS
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Fig. 1. Sub-study 1: plasma Pro-MMP-9 concentrations in healthy (n=35) and MS pa-
tients (n=36). Mean values and S.D. for patients and controls are given. *Pb0.05 vs.
healthy individuals by one-way analysis of variance, followed by Bonferroni's multiple
comparison test selected pair comparisons.2.2. Genotyping
Subjects were genotyped for C−1562T polymorphism by polymer-
ase chain reaction (PCR) ampliﬁcation using the primers 5′-GCC TGG
CAC ATA GTA GGC CC-3′ (sense) and 5′-CTT CCT AGC CAG CCG
GCATC-3′ (antisense), following the previously described PCR condi-
tions (Zhang et al., 1999). The ampliﬁed products were digested
with Sph I (New England Biolabs, Ipswich, MA, USA) overnight at
37 °C, generating fragments of 247 and 188 bp in the case of a poly-
morphic variant (allele “T”), or an undigested 435 bp band in the
case of a wild type allele (allele “C”). Fragments were separated by
electrophoresis in 12% polyacrylamide gels and visualized by silver
staining as described earlier (Demacq et al., 2006). Some recognized
DNA variants were genotyped in parallel as RFLP technique controls.
To determine the genotypes for the (CA)n polymorphism, PCR was
carried out using the primers 5′-GAC TTG GCA GTG GAG ACT GCG
GGC A-3′ (sense) and 5′-GAC CCC ACC CCT CCT TGA CAG GCA A-3′
(antisense), as previously described (Maeda et al., 2001). The PCRs
were performed in a 25 μL mixture containing 500 ng DNA, 20 pmol
of each primer, 0.2 mM of each dNTP, 1.5 mM MgCl2, 1.0 U Taq poly-
merase, and 2.5 μL 10× PCR buffer. After initial denaturation at 95 °C
for 3 min, the samples were subjected to 30 cycles of ampliﬁcation,
which consisted of denaturation for 1 min at 95 °C, annealing for
1 min at 69 °C, and extension for 1 min at 72 °C, followed by a ﬁnal
extension for 10 min. The ampliﬁed products were separated in a 7%
polyacrylamide–urea gel and visualized by silver staining (Demacq
et al., 2008). Differences in molecular weight (or number of bases)
from 144 bp (13 repeats) to 168 bp (25 repeats) were determined
by comparison with migration of a 10 bp DNA ladder (Invitrogen Cor-
poration, Carlsbad, CA, USA) and with some samples from homozy-
gotes that had been sequenced. DNA sequencing of control
homozygote variants had been accomplished, in order to verify the
precise CA repeat numbers. This procedure was standardized as de-
scribed earlier (Nelissen et al., 2000; Demacq et al., 2008). The sam-
ples were classiﬁed as lower (L) than 21 CA repeats or higher (H)
than 21 CA repeats.2.3. MMP-9 SDS-polyacrylamide gel electrophoresis gelatin zymography
Plasma MMP-9 gelatin zymography was conducted as previously
described (Demacq et al., 2008). Brieﬂy, plasma samples were sub-
jected to electrophoresis on 7% SDS-PAGE co-polymerized with gela-
tin (1%) as the substrate. After the electrophoresis was complete, the
gel was incubated for 1 h at room temperature in a 2% Triton X-100
solution, followed by incubation at 37 °C for 16 h in Tris–HCl buffer,
pH 7.4, containing 10 mmol/L CaCl2. The gels were stained with
0.05% Coomassie Brilliant Blue G-250, followed by destaining with
30% methanol and 10% acetic acid. Gelatinolytic activities were
detected as unstained bands against the background of Coomassie
blue-stained gelatin. Enzyme activity was assayed by densitometry
using a Kodak Electrophoresis Documentation and Analysis System
(EDAS) 290 (Kodak, Rochester, NY). Only the pro-form (pro-) MMP-
9 bands were analyzed, identiﬁed as bands at 92 kDa by the relation
of log Mr to the relative mobility of Sigma SDS-PAGE LMW marker
proteins.
2.4. Statistical analysis
Continuous variable was compared by the unpaired Student's t-
test or ANOVA. Contingency table-based analysis was used for com-
parisons of nominal variables, including genotype frequencies. Data
were reported as the mean±S.D. The group comparisons were
assessed by one-way analysis of variance, followed by Bonferroni's
multiple comparison test selected pair comparisons. A P valueb0.05
was considered as the minimum level of statistical signiﬁcance.
3. Results
3.1. Sub-study 1
Healthy volunteers andMS patients were matched for gender, age,
and ethnicity, with no signiﬁcant difference between groups. Plasma
MMP-9 levels were compared between MS and healthy individuals
groups. As expected, plasma MMP-9 levels were signiﬁcantly higher
in MS patients than those measured in healthy volunteers (1.4±
0.18 versus 0.93±0.18 A.U., respectively Pb0.05, Fig. 1).
3.2. Sub-study 2
Interestingly, when MS participants were analyzed for drug resis-
tance, patients with more than 2 relapses in a period of 2 years, clas-
siﬁed as resistant to therapy, presented signiﬁcantly higher plasma
MMP-9 levels (61%) as compared to responsive patients (1.96±0.25
versus 1.21±0.09 A.U., respectively Pb0.05, Fig. 2A).
When MS patients were classiﬁed by clinical status, the results in-
dicated a progressively increasing plasma MMP-9 activity in more se-
verely affected groups, as represented by the EDSS score range
Fig. 2. Sub-study 2: plasma Pro-MMP-9 concentrations in patients that are non-resistant (NR) and resistant (R) to drug therapy, in patients classiﬁed by degree of severity (S1–S4),
and in patients that carry genotypes of C−1562T (rs3918242) as C T alleles, and of microsatellite (CA)n 13–25 (rs3222264) as low L and/or High alleles (n=53). Mean values and S.D.
for patients and controls are given. *Pb0.05 vs. healthy individuals by one-way analysis of variance, followed by Bonferroni's multiple comparison test selected pair comparisons.
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MMP-9 values as compared to S1 (2.62±0.63 A.U. versus 1.02±
0.37 A.U.).
Our group has already described that MMP-9 genotypes and hap-
lotypes are associated with MS and with the degree of disability
caused by the disease (Fernandes et al., 2009). The genotype frequen-
cies in the MS population evaluated here (n=53) were 75% CC, 23%
CT, and 2% TT for the C−1562T polymorphism, and 15% LL, 38% LH,
and 47% HH for the (CA)n polymorphism, as shown in Fig. 2C and D.
In the control group (n=35), CC, CT, and TT genotype frequencies
were 77%, 20%, and 3%, respectively. Regarding (CA)n polymorphism,
17%, 43%, and 40% of the subjects were LL, LH and HH, respectively.
The distribution of genotypes for the two polymorphisms studied
herein showed no deviation from the Hardy–Weinberg equilibrium
in control and MS groups.
In the present study, it has been investigated whether MMP-9
C−1562T and (CA)n polymorphisms are related to MMP-9 activity in
control and MS individuals. Since the TT genotype frequency is very
low, both CT and TT carriers were grouped. There was a signiﬁcant
difference in the plasma MMP-9 levels of MS patients that presented
C to T substitution (CT+TT carriers). Patients carrying CC genotype
presented plasma MMP-9 levels of 1.21±0.06 A.U. as compared to
2.13±0.016 A.U. found in the CT+TT group (Pb0.0001, Fig. 2C). In
addition, an overall different distribution of plasma MMP-9 levels
was observed among (CA)n genotypes (Pb0.04; Fig. 2B). It was veri-
ﬁed that MS patients with the HH genotype, who carry a higher num-
ber of CA repeats in the MMP-9 gene, tended to exhibit higher (about
55%) pro-MMP-9 activity as compared to genotypes with lower (CA)
numbers (Fig. 2D). However, control subjects displayed equal MMP-9
activity among genotypes for both polymorphisms. Healthy individ-
uals carrying CT+TT genotypes presented plasma MMP-9 levels of
0.59±0.38 A.U. as compared to 0.45±0.38 A.U. found in the CC
group (P>0.05). Similarly, carriers of the HH genotype had plasma
MMP-9 levels of 0.51±0.39 A.U., whereas HL and LL genotypes pre-
sented 0.36±0.27 and 0.54±0.50 A.U. (P>0.05), respectively.
4. Discussion
It has been described that MMP-9 is involved in MS pathogenesis
(Gijbels et al., 1992; Liuzzi et al., 2002; Avolio et al., 2003; Boz et al.,2006; Fainardi et al., 2006). Our results are corroborated by previous
reports that have demonstrated elevated MMP-9 levels in the serum
(Lee et al., 1999; Waubant et al., 1999) and cerebrospinal ﬂuid
(Leppert et al., 1998; Lichtinghagen et al., 1999) of MS patients. Al-
though these previous studies have not measured MMP-9 in plasma,
determination of plasma MMP-9 activity by zymography has been
used as an excellent MMP-9 biomarker, once the plasma is free of
platelet activation derivatives, which cause augmentation of MMP-9
activity (Souza-Tarla et al., 2005; Gerlach et al., 2005, 2007).
When MS patients were classiﬁed according to the degree of dis-
ability and plasma MMP-9 levels were measured, we found that se-
vere disability status was related to higher MMP-9 levels. The time
course of MMP-9 regulation in MS patients is unclear. MMP activity
does not seem to be regulated between relapses and stable phases
(Leppert et al., 1998). However, our ﬁndings suggest that patients
with more than 2 relapses during a two year drug therapy follow-
up period (drug resistance) present higher MMP-9 levels as com-
pared to patients that responded to therapy. Thus, active phases
could be related to higher MMP-9 activity. Our analysis was related
to episodes that occurred irrespective of the drug used during the
treatment. These data are in consonance with other results describing
that MS patients classiﬁed as responders to IFN-beta treatment (pre-
senting no relapses over 2 years of treatment) have their MMP-9/
TIMP-1 balance restored (Boz et al., 2006; Comabella et al., 2009).
The second part of this study aimed to correlate MMP-9 C−1562T
and (CA)n polymorphisms with plasma MMP-9 levels. In vitro studies
have shown that the C to T substitution at the−1562 position results
in loss of a nuclear repressor protein binding, thus leading to in-
creased MMP-9 expression (Zhang et al., 1999). The microsatellite
(CA)n near the −90 position of the MMP-9 gene, which corresponds
to a sequence of variable numbers of cytosine–adenine repeats
(13–27) and has a bimodal distribution of allele frequencies (peaks
in CA≤14 and CA≥21–23) (Shimajiri et al., 1999), also seems to be
functionally relevant. This polymorphism displays alleles represent-
ing lower repeats (L), thereby eliciting a 50% reduction in the MMP-
9 promoter activity as compared to higher repeat alleles (H), which
enhance such activity. In accordance with these in vitro studies, we
found that MS patients carrying the T allele (CT+TT genotypes) or
the HH genotype present signiﬁcantly higher plasma MMP-9 levels.
These results agree with our previous report showing that genotypes
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patients with higher degree of disability (Fernandes et al., 2009). The
data presented here indicate that these polymorphisms are functional
in MS patient, as determined by plasma MMP-9 levels. The low num-
ber of patients analyzed in the present study has not allowed for the
establishment of a correlation among drug resistance, degree of dis-
ability, and plasma MMP-9 levels. However, the MMP-9 genotype
analysis could be a way of selecting a speciﬁc group of patients
prone to be responders to pharmacological intervention with MMP-
9 inhibitors as adjuvant of MS classical therapies.
Our results are reinforced by the haplotype analysis of MS pa-
tients. We have earlier described that haplotypes of the MMP-9
C−1562T and (CA)n polymorphisms are associated with the degree
of disability in a Brazilian population of MS patients (Fernandes et
al., 2009). The results of the latter study showed that the T-L haplo-
type is signiﬁcantly more frequent in severely affected patients as
compared to controls. These previous data have been recently corrob-
orated by a study reporting that individuals carrying the same T-L
haplotype are more susceptible to MS initiation in an Italian popula-
tion (La Russa et al., 2010), thus supporting the hypothesis that an
important role is played by the MMP-9 gene in MS. Interestingly,
the MS patients participating in our studies were tested predomi-
nantly for the DRB*1501 allele and also have a predominant Italian
ancestry (Brum et al., 2007), again reinforcing this hypothesis. Re-
cently, a GWAS has reported strong evidence of association between
the SNP (rs2425752) and multiple sclerosis patients (International
Multiple Sclerosis Genetics Consortium et al., 2011). This SNP is locat-
ed in the CD40 gene that is very close to the MMP-9 gene (about
66,000 bp from C−1562T), suggesting that both variants may be relat-
ed to MS. The small sample size of the current study hinders an anal-
ysis addressing this issue. In conclusion, our ﬁndings point to an
important role played by MMP-9 polymorphisms in modulating cir-
culating MMP-9 production in individuals affected by MS. Moreover,
the MMP-9 genotypic approach to MS may be useful as a prognostic
biomarker of drug resistance andmay aid recommendation of new vi-
able possibilities of therapeutic intervention.
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